Literature DB >> 9625548

Visual function after foveal translocation with scleral shortening in patients with myopic neovascular maculopathy.

T Fujikado1, M Ohji, Y Saito, A Hayashi, Y Tano.   

Abstract

PURPOSE: To document the visual outcome after successful foveal translocation with intentional retinal detachment and scleral shortening for the treatment of myopic neovascular maculopathy.
METHODS: Two severely myopic patients with subfoveal neovascular membranes underwent surgical translocation of the fovea to an area of healthy retinal pigment epithelium by means of scleral shortening and intentional retinal detachment. In the postoperative period, monocular and binocular visual function were studied.
RESULTS: In one patient, best-corrected visual acuity improved from 20/150 to 20/20 postoperatively. In the second patient, acuity initially improved from 20/70 to 20/30. In both patients, the fixation point shifted from the site of the neovascular membrane. Oblique astigmatism developed and was managed with hard contact lenses. Diplopia and subjective torsion occurred transiently. Micropsia occurred in one patient. Peripheral fusion assessed by Worth four-dot testing after resolution of diplopia disclosed suppression in the nondominant eye in both cases.
CONCLUSIONS: Foveal translocation with intentional retinal detachment and scleral shortening was useful in improving visual acuity in two patients with myopic neovascular maculopathy. Diplopia and aniseikonia occurred but resolved over time as suppression developed. This technique is promising for patients with myopic neovascular maculopathy.

Entities:  

Mesh:

Year:  1998        PMID: 9625548     DOI: 10.1016/s0002-9394(98)00021-x

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  9 in total

1.  Foveal relocation by redistribution of the neurosensory retina.

Authors:  D Wong; N Lois
Journal:  Br J Ophthalmol       Date:  2000-04       Impact factor: 4.638

2.  Electrophysiological changes after 360 degrees retinotomy and macular translocation for subfoveal choroidal neovascularisation in age related macular degeneration.

Authors:  C Lüke; S Aisenbrey; M Lüke; G Marzella; K U Bartz-Schmidt; P Walter
Journal:  Br J Ophthalmol       Date:  2001-08       Impact factor: 4.638

3.  Simultaneous translocation of the macula and underlying retinal pigment epithelium during macular translocation surgery in a patient with long standing myopic neovascular maculopathy.

Authors:  M Ichibe; K Imai; M Ohta; Y Oya; T Yoshizawa; H Abe
Journal:  Br J Ophthalmol       Date:  2003-03       Impact factor: 4.638

4.  Electro-oculographic findings after 360 degrees retinotomy and macular translocation for subfoveal choroidal neovascularisation in age-related macular degeneration.

Authors:  Christoph Lüke; Nils Alteheld; Sabine Aisenbrey; Matthias Lüke; Karl Ulrich Bartz-Schmidt; Peter Walter; Bernd Kirchhof
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2003-08-23       Impact factor: 3.117

Review 5.  Choroidal neovascularisation in pathological myopia: an update in management.

Authors:  W-M Chan; M Ohji; T Y Y Lai; D T L Liu; Y Tano; D S C Lam
Journal:  Br J Ophthalmol       Date:  2005-11       Impact factor: 4.638

6.  Limited macular translocation with scleral retraction suture.

Authors:  P Sullivan; L Filsecker; J Sears
Journal:  Br J Ophthalmol       Date:  2002-04       Impact factor: 4.638

7.  Photodynamic therapy with verteporfin for subfoveal choroidal neovascularisation of pathologic myopia in Chinese eyes: a prospective series of 1 and 2 year follow up.

Authors:  D S C Lam; W-M Chan; D T L Liu; D S P Fan; W W Lai; K K L Chong
Journal:  Br J Ophthalmol       Date:  2004-10       Impact factor: 4.638

8.  Verteporfin photodynamic therapy in highly myopic subfoveal choroidal neovascularisation.

Authors:  J A Montero; J M Ruiz-Moreno
Journal:  Br J Ophthalmol       Date:  2003-02       Impact factor: 4.638

9.  Subretinal fibrosis after photodynamic therapy in subfoveal choroidal neovascularisation in highly myopic eyes.

Authors:  J M Ruiz-Moreno; J A Montero
Journal:  Br J Ophthalmol       Date:  2003-07       Impact factor: 4.638

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.